NCT04016077View on ClinicalTrials.gov

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of PF-06651600 in Subjects With Hepatic Impairment and Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

July 19, 2019

Primary Completion Date

March 5, 2020

Study Completion Date

March 5, 2020

Conditions
Hepatic ImpairmentHealthy Participants
Interventions
DRUG

PF-06651600 30 mg

PF-06651600 in 10 mg oral tablets will be administered on days 1 to 10.

Trial Locations (2)

32809

Orlando Clinical Research Center, Orlando

33136

University of Miami Division of Clinical Pharmacology, Miami

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT04016077 - A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of PF-06651600 in Subjects With Hepatic Impairment and Healthy Volunteers | Biotech Hunter | Biotech Hunter